235 related articles for article (PubMed ID: 20922679)
1. [Lights and shadows on single and dual RAAS blockade].
Cavalli A; Del Vecchio L; Locatelli F
G Ital Nefrol; 2010; 27(5):477-89. PubMed ID: 20922679
[TBL] [Abstract][Full Text] [Related]
2. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
3. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
5. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
9. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
Tylicki L; Lizakowski S; Rutkowski B
J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
14. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
15. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
16. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
Ryan MJ; Tuttle KR
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
[TBL] [Abstract][Full Text] [Related]
17. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
18. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
20. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
